Delivery Order SPE2DB20D9127-SPE2DB25FPRD3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector units. This firm fixed-price delivery order, issued on September 8, 2025, with a completion date of September 29, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA. The IDC,...
- The Defense Logistics Agency awarded a $51,366.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, represents a specific fulfillment order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector units. This delivery order, issued on May 30, 2025, with a completion date of June 23, 2025, operates under a firm fixed-price structure with no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair auto-injectors valued at $1,712.22. This delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, utilizes firm fixed-price pricing and was awarded without set-aside designation. The award is issued under DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml autoinjector. The contract, valued at $1,712.22 with a firm fixed-price arrangement, is set to be completed by October 9, 2025, following the award date of September 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $34,244.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, was awarded without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,712.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/ml autoinjectors, with a period of performance through October 3, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of September 5, 2025, represents a specific fulfillment under the company's larger Indefinite Delivery Contract with DLA valued at $499,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $27,395.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector medications. This firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of September 10, 2025, and does not utilize a set-aside designation. The award represents a specific fulfillment under DMS Pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $44,651.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a standard procurement action with no set-aside designation. The award falls under DMS Pharmaceutical Group's larger...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRD3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical items supporting medical supply needs across military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively in DLA procurement. The company specializes in distributing branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to Department of Defense healthcare facilities nationwide. Xolair is a monoclonal antibody treatment commonly used for moderate-to-severe allergic asthma and chronic idiopathic urticaria, making this auto-injector delivery consistent with the company's portfolio of specialized pharmaceutical products supplied to federal military health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 8/15/25 |